Search Results - "Ramaekers, Bram L"

Development and Validation of the TRansparent Uncertainty ASsessmenT (TRUST) Tool for Assessing Uncertainties in Health Economic Decision Models by Grimm, Sabine E., Pouwels, Xavier, Ramaekers, Bram L. T., Wijnen, Ben, Knies, Saskia, Grutters, Janneke, Joore, Manuela A.

“…Background An increasing number of technologies are obtaining marketing authorisation based on sparse evidence, which causes growing uncertainty and risk…”
Get full text

State of the ART? Two New Tools for Risk Communication in Health Technology Assessments by Grimm, Sabine E., Pouwels, Xavier, Ramaekers, Bram L. T., Wijnen, Ben, Otten, Thomas, Grutters, Janneke, Joore, Manuela A.

“…Purpose Outcomes of health technology assessments (HTA) are uncertain, and decision-making is associated with a risk. This risk, consisting of the probability…”
Get full text

Reviewing the quality, health benefit and value for money of chemotherapy and targeted therapy for metastatic breast cancer by Pouwels, Xavier Ghislain Léon Victor, Ramaekers, Bram L. T., Joore, Manuela A.

“…Purpose To provide an overview of model characteristics and outcomes of model-based economic evaluations concerning chemotherapy and targeted therapy (TT) for…”
Get full text

Correction to: Building a trusted framework for uncertainty assessment in rare diseases: suggestions for improvement (Response to “TRUST4RD: tool for reducing uncertainties in the evidence generation for specialised treatments for rare diseases”) by Grimm, Sabine E, Pouwels, Xavier, Ramaekers, Bram L. T, Wijnen, Ben, Knies, Saskia, Grutters, Janneke, Joore, Manuela A

Get full text

Building a trusted framework for uncertainty assessment in rare diseases: suggestions for improvement (Response to "TRUST4RD: tool for reducing uncertainties in the evidence generation for specialised treatments for rare diseases") by Grimm, Sabine E, Pouwels, Xavier, Ramaekers, Bram L T, Wijnen, Ben, Knies, Saskia, Grutters, Janneke, Joore, Manuela A

“…The aim of this letter to the editor is to provide a comprehensive summary of uncertainty assessment in Health Technology Assessment, with a focus on…”
Get full text

Arsenic Trioxide for Treating Acute Promyelocytic Leukaemia: An Evidence Review Group Perspective of a NICE Single Technology Appraisal by Ramaekers, Bram L. T., Riemsma, Rob, Grimm, Sabine, Fayter, Debra, Deshpande, Sohan, Armstrong, Nigel, Witlox, Willem, Pouwels, Xavier, Duffy, Steven, Worthy, Gill, Kleijnen, Jos, Joore, Manuela A.

“…The National Institute for Health and Care Excellence (NICE) invited Teva, the company manufacturing arsenic trioxide (ATO; tradename Trisenox ® ), to submit…”
Get full text

Comment on “External Validation of the Core Obesity Model to Assess the Cost-Effectiveness of Weight Management Interventions” by Ramaekers, Bram L. T., Wijnen, Ben, Armstrong, Nigel, Petersohn, Svenja, Feenstra, Talitha, Wang, Junfeng, Joore, Manuela A.

Get full text

Spacers in radiotherapy treatment of prostate cancer: Is reduction of toxicity cost-effective? by Vanneste, Ben G.L, Pijls-Johannesma, Madelon, Van De Voorde, Lien, van Lin, Emile N, van de Beek, Kees, van Loon, Judith, Ramaekers, Bram L, Lambin, Philippe

“…Abstract Background and purpose To compare the cost-effectiveness of treating prostate cancer patients with intensity-modulated radiation therapy and a spacer…”
Get full text

Early Cost Effectiveness of Whole-Genome Sequencing as a Clinical Diagnostic Test for Patients with Inoperable Stage IIIB,C/IV Non-squamous Non-small-Cell Lung Cancer by Simons, Martijn J. H. G., Retèl, Valesca P., Ramaekers, Bram L. T., Butter, Rogier, Mankor, Joanne M., Paats, Marthe S., Aerts, Joachim G. J. V., Mfumbilwa, Zakile A., Roepman, Paul, Coupé, Veerle M. H., Uyl-de Groot, Carin A., van Harten, Wim H., Joore, Manuela A.

“…Background Advanced non-small-cell lung cancer (NSCLC) harbours many genetic aberrations that can be targeted with systemic treatments. Whole-genome sequencing…”
Get full text

Quality of life in a real-world cohort of advanced breast cancer patients: a study of the SONABRE Registry by Claessens, Anouk K. M., Ramaekers, Bram L. T., Lobbezoo, Dorien J. A., van Kampen, Roel J. W., de Boer, Maaike, van de Wouw, Agnes J., Dercksen, M. Wouter, Geurts, Sandra M. E., Joore, Manuela A., Tjan-Heijnen, Vivianne C. G.

“…Purpose We aimed to evaluate quality of life (QoL) using the European Quality of Life Five-Dimensions questionnaire (EQ-5D-3L) in a real-world cohort of Dutch…”
Get full text

Nivolumab for Treating Metastatic or Unresectable Urothelial Cancer: An Evidence Review Group Perspective of a NICE Single Technology Appraisal by Grimm, Sabine E., Armstrong, Nigel, Ramaekers, Bram L. T., Pouwels, Xavier, Lang, Shona, Petersohn, Svenja, Riemsma, Rob, Worthy, Gillian, Stirk, Lisa, Ross, Janine, Kleijnen, Jos, Joore, Manuela A.

“…As part of its single technology appraisal (STA) process, the National Institute for Health and Care Excellence (NICE) invited the manufacturer (Bristol-Myers…”
Get full text

Pembrolizumab for Treating Relapsed or Refractory Classical Hodgkin Lymphoma: An Evidence Review Group Perspective of a NICE Single Technology Appraisal by Grimm, Sabine E., Fayter, Debra, Ramaekers, Bram L. T., Petersohn, Svenja, Riemsma, Rob, Armstrong, Nigel, Pouwels, Xavier, Witlox, Willem, Noake, Caro, Worthy, Gillian, Kleijnen, Jos, Joore, Manuela A.

“…As part of its Single Technology Appraisal (STA) process, the National Institute for Health and Care Excellence (NICE) invited the manufacturer (Merck Sharp &…”
Get full text

Exploring the Feasibility of Comprehensive Uncertainty Assessment in Health Economic Modeling: A Case Study by Petersohn, Svenja, Grimm, Sabine E., Ramaekers, Bram L.T., ten Cate-Hoek, Arina J., Joore, Manuela A.

“…Decision makers adopt health technologies based on health economic models that are subject to uncertainty. In an ideal world, these models parameterize all…”
Get full text

Trifluridine–Tipiracil for Previously Treated Metastatic Colorectal Cancer: An Evidence Review Group Perspective of a NICE Single Technology Appraisal by Ramaekers, Bram L. T., Wolff, Robert, van Giessen, Anoukh, Pouwels, Xavier, Fayter, Debra, Lang, Shona, Armstrong, Nigel, Worthy, Gill, Duffy, Steven, Kleijnen, Jos, Joore, Manuela A.

“…The National Institute for Health and Care Excellence (NICE) invited Servier, the company manufacturing trifluridine and tipiracil (T/T; trade name: Lonsurf ®…”
Get full text

The impact of late treatment-toxicity on generic health-related quality of life in head and neck cancer patients after radiotherapy by Ramaekers, Bram L.T, Joore, Manuela A, Grutters, Janneke P.C, van den Ende, Piet, Jong, Jos de, Houben, Ruud, Lambin, Philippe, Christianen, Miranda, Beetz, Ivo, Pijls-Johannesma, Madelon, Langendijk, Johannes A

“…Summary To examine the impact of late treatment-related xerostomia and dysphagia on health-related quality of life (HRQOL) in head and neck cancer (HNC)…”
Get full text

Ixekizumab for Treating Moderate-to-Severe Plaque Psoriasis: An Evidence Review Group Perspective of a NICE Single Technology Appraisal by Ramaekers, Bram L. T., Wolff, Robert F., Pouwels, Xavier, Oosterhoff, Marije, Van Giessen, Anoukh, Worthy, Gill, Noake, Caro, Armstrong, Nigel, Kleijnen, Jos, Joore, Manuela A.

“…The National Institute for Health and Care Excellence invited Eli Lilly and Company Ltd, the company manufacturing ixekizumab (tradename Taltz ® ), to submit…”
Get full text

Acknowledging Patient Heterogeneity in Economic Evaluation: A Systematic Literature Review by Grutters, Janneke P. C., Sculpher, Mark, Briggs, Andrew H., Severens, Johan L., Candel, Math J., Stahl, James E., De Ruysscher, Dirk, Boer, Albert, Ramaekers, Bram L. T., Joore, Manuela A.

“…Background and Objective Patient heterogeneity is the part of variability that can be explained by certain patient characteristics (e.g. age, disease stage)…”
Get full text

Response to “UNCERTAINTY MANAGEMENT IN REGULATORY AND HEALTH TECHNOLOGY ASSESSMENT DECISION-MAKING ON DRUGS: GUIDANCE OF THE HTAi-DIA WORKING GROUP” by Grimm, Sabine Elisabeth, Pouwels, Xavier G.L.V., Ramaekers, Bram L.T., Wijnen, Ben, Grutters, Janneke, Joore, Manuela A.

Get full text

Uncertainty and Coverage With Evidence Development: Does Practice Meet Theory? by Pouwels, Xavier G.L.V., Grutters, Janneke P.C., Bindels, Jill, Ramaekers, Bram L.T., Joore, Manuela A.

“…In theory, a successful coverage with evidence development (CED) scheme is one that addresses the most important uncertainties in a given assessment. We…”
Get full text

Abiraterone Acetate for the Treatment of Chemotherapy-Naïve Metastatic Castration-Resistant Prostate Cancer: An Evidence Review Group Perspective of an NICE Single Technology Appraisal by Ramaekers, Bram L. T., Riemsma, Rob, Tomini, Florian, van Asselt, Thea, Deshpande, Sohan, Duffy, Steven, Armstrong, Nigel, Severens, Johan L., Kleijnen, Jos, Joore, Manuela A.

“…The National Institute for Health and Care Excellence (NICE) invited Janssen, the company manufacturing abiraterone acetate (AA; tradename Zytiga ® ), to…”
Get full text